Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription 17.09.2018 1 Am J Clin Oncol 2 Ann Oncol 1 Ann Surg Oncol 9 Anticancer Res 1 Br J Cancer 2 Chest 3 Clin Cancer Res 6 Clin Lung Cancer 1 Eur J Cardiothorac Surg 2 J Clin Oncol 1 J Surg Oncol 1 J Thorac Cardiovasc Surg 4 J Thorac Oncol 1 Lung Cancer (Auckl) 6 N Engl J Med 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. GIBSON AJW, Li H, D'Silva A, Tudor RA, et al
   Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Non-Small Cell Lung Cancer.
   Am J Clin Oncol. 2018 Sep 11. doi: 10.1097/COC.0000000000000483.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

2. GADGEEL S, Peters S, Mok T, Shaw AT, et al
   Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
   Ann Oncol. 2018 Sep 12. pii: 5095692. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
3. TANIGUCHI Y, Takeda M, Tamiya A, Kasai T, et al
   Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small cell lung cancer.
   Ann Oncol. 2018 Sep 10. pii: 5094491. doi: 10.1093.
   PubMed     Text format    
   
   

   
   Ann Surg Oncol

4. ARNDT AT
   A Little Bit of Cancer is Still Cancer: Is it Time for Lymph Node Micrometastases in Non-small Cell Lung Cancer to Get Their Due?
   Ann Surg Oncol. 2018 Sep 10. pii: 10.1245/s10434-018-6747.
   PubMed     Text format    
   
   

   
   Anticancer Res

5. RONCHI L, Buwenge M, Cortesi A, Ammendolia I, et al
   Whole Lung Irradiation in Patients with Osteosarcoma and Ewing Sarcoma.
   Anticancer Res. 2018;38:4977-4985.
   PubMed     Text format     Abstract available
   
   
6. MILLETT RL, Elkon JM, Tabbara IA
   Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
   Anticancer Res. 2018;38:4969-4975.
   PubMed     Text format     Abstract available
   
   
7. HAKOZAKI M, Tamura H, Dobashi Y, Yoshida A, et al
   Establishment and Characterization of a Novel Human Clear-cell Sarcoma of Soft-tissue Cell Line, RSAR001, Derived from Pleural Effusion of a Patient with Pleural Dissemination.
   Anticancer Res. 2018;38:5035-5042.
   PubMed     Text format     Abstract available
   
   
8. LEE J, Yun HH, Kim S, Ji SH, et al
   Implication of BIS in the Migration and Invasion of A549 Non-small Cell Lung Cancer Cells.
   Anticancer Res. 2018;38:5057-5065.
   PubMed     Text format     Abstract available
   
   
9. KURAMOTO K, Yamamoto M, Suzuki S, Sanomachi T, et al
   AS602801, an Anti-Cancer Stem Cell Drug Candidate, Suppresses Gap-junction Communication Between Lung Cancer Stem Cells and Astrocytes.
   Anticancer Res. 2018;38:5093-5099.
   PubMed     Text format     Abstract available
   
   
10. HUANG YP, Jiang YW, Chen HY, Hsiao YT, et al
    Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro.
    Anticancer Res. 2018;38:5165-5176.
    PubMed     Text format     Abstract available
    
    
11. WU JY, Lin SS, Hsu FT, Chung JG, et al
    Fluoxetine Inhibits DNA Repair and NF-kB-modulated Metastatic Potential in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5201-5210.
    PubMed     Text format     Abstract available
    
    
12. EZE C, Roengvoraphoj O, Dantes M, Abdo R, et al
    Prophylactic Cranial Irradiation for Patients with Small Cell Lung Cancer in Germany: Pattern of Care Survey.
    Anticancer Res. 2018;38:5261-5265.
    PubMed     Text format     Abstract available
    
    
13. TAKEUCHI A, Oguri T, Yamashita Y, Sone K, et al
    TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5489-5495.
    PubMed     Text format     Abstract available
    
    

    
    Br J Cancer

14. SASAKI T, Seto T, Yamanaka T, Kunitake N, et al
    A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L.
    Br J Cancer. 2018 Sep 12. pii: 10.1038/s41416-018-0243.
    PubMed     Text format     Abstract available
    
    

    
    Chest

15. TAMURA T, Miyazaki K, Satoh H
    Features of COPD as Predictors of Lung Cancer.
    Chest. 2018;154:720-721.
    PubMed     Text format    
    
    
16. REICH JM
    Reservations Regarding Lung Cancer Screening Guidelines.
    Chest. 2018;154:715-716.
    PubMed     Text format    
    
    

    
    Clin Cancer Res

17. LO RUSSO G, Moro M, Sommariva M, Cancila V, et al
    Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-1390.
    PubMed     Text format     Abstract available
    
    
18. PETERS S, Stahel RA, Bubendorf L, Bonomi P, et al
    Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety and Biomarkers.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-1590.
    PubMed     Text format     Abstract available
    
    
19. CORREDOR G, Wang X, Zhou Y, Lu C, et al
    Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non-small cell lung cancer.
    Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-2013.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

20. OWEN DH, Wei L, Bertino EM, Edd T, et al
    Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.
    Clin Lung Cancer. 2018 Aug 22. pii: S1525-7304(18)30202.
    PubMed     Text format     Abstract available
    
    
21. WU F, Lin X, Yang Z, Sun Z, et al
    Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
    Clin Lung Cancer. 2018 Aug 23. pii: S1525-7304(18)30200.
    PubMed     Text format     Abstract available
    
    
22. HATA A, Katakami N, Shimokawa M, Mitsudomi T, et al
    Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
    Clin Lung Cancer. 2018 Aug 7. pii: S1525-7304(18)30193.
    PubMed     Text format     Abstract available
    
    
23. WAINER Z, Wright GM, Gough K, Daniels MG, et al
    Sex-Dependent Staging in Non-Small-Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System.
    Clin Lung Cancer. 2018 Aug 22. pii: S1525-7304(18)30198.
    PubMed     Text format     Abstract available
    
    
24. SUZUKI R, Wei X, Allen PK, Welsh JW, et al
    Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis.
    Clin Lung Cancer. 2018 Aug 22. pii: S1525-7304(18)30206.
    PubMed     Text format     Abstract available
    
    
25. IAMS WT, Yu H, Shyr Y, Patil T, et al
    First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
    Clin Lung Cancer. 2018 Aug 22. pii: S1525-7304(18)30205.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cardiothorac Surg

26. CHIAPPETTA M, Leuzzi G, Sperduti I, Bria E, et al
    Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis.
    Eur J Cardiothorac Surg. 2018 Sep 6. pii: 5092028. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

27. WARDAK Z, Choy H
    Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016;34:4064-4065.
    PubMed     Text format    
    
    
28. ZENG L, Yang N, Zhang Y
    Should Crizotinib Take It All in ROS1-Positive Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2018 Sep 13:JCO1800119. doi: 10.1200/JCO.18.00119.
    PubMed     Text format    
    
    

    
    J Surg Oncol

29. QUERO-VALENZUELA F, Piedra-Fernandez I, Hernandez-Escobar F
    Readmission after pulmonary resection for lung cancer.
    J Surg Oncol. 2018 Sep 9. doi: 10.1002/jso.25207.
    PubMed     Text format    
    
    

    
    J Thorac Cardiovasc Surg

30. FERNANDEZ-RODRIGUEZ L, Torres I, Romera D, Galera R, et al
    Prediction of postoperative lung function after major lung resection for lung cancer using volumetric computed tomography.
    J Thorac Cardiovasc Surg. 2018 Aug 2. pii: S0022-5223(18)32018.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Oncol

31. LE-RADEMACHER J, Dahlberg S, Lee JJ, Adjei AA, et al
    Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations.
    J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33034.
    PubMed     Text format     Abstract available
    
    
32. DENG W, Xu T, Wang Y, Xu Y, et al
    Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach.
    J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33036.
    PubMed     Text format     Abstract available
    
    
33. DESCARPENTRIES C, Lepretre F, Escande F, Kherrouche Z, et al
    Optimization of routine testing for MET exon 14 splice site mutations in non-small cell lung cancer patients.
    J Thorac Oncol. 2018 Sep 6. pii: S1556-0864(18)33038.
    PubMed     Text format     Abstract available
    
    
34. LIN JJ, Chin E, Yeap BY, Ferris LA, et al
    Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33040.
    PubMed     Text format     Abstract available
    
    

    
    Lung Cancer (Auckl)

35. ALBANO D, Bilfinger T, Nemesure B
    1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT.
    Lung Cancer (Auckl). 2018;9:65-71.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

36. GIL-SIERRA MD, Fenix-Caballero S, Alegre-del Rey E
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e19.
    PubMed     Text format    
    
    
37. DIKER O
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e18.
    PubMed     Text format    
    
    
38. SUN R, Rich MW, Wei LJ
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e18.
    PubMed     Text format    
    
    
39. VANDERLAAN PA, Rangachari D, Costa DB
    Lung Cancer with a High Tumor Mutational Burden.
    N Engl J Med. 2018;379:1093.
    PubMed     Text format    
    
    
40. 
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e18.
    PubMed     Text format    
    
    
41. 
    Lung Cancer with a High Tumor Mutational Burden.
    N Engl J Med. 2018;379:1093-1094.
    PubMed     Text format    
    
    

    
    PLoS One

42. CONSONNI D, Carugno M, De Matteis S, Nordio F, et al
    Outdoor particulate matter (PM10) exposure and lung cancer risk in the EAGLE study.
    PLoS One. 2018;13:e0203539.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: